SG11201903659WA - Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications - Google Patents

Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Info

Publication number
SG11201903659WA
SG11201903659WA SG11201903659WA SG11201903659WA SG11201903659WA SG 11201903659W A SG11201903659W A SG 11201903659WA SG 11201903659W A SG11201903659W A SG 11201903659WA SG 11201903659W A SG11201903659W A SG 11201903659WA SG 11201903659W A SG11201903659W A SG 11201903659WA
Authority
SG
Singapore
Prior art keywords
international
aulx
ouates
les
plane
Prior art date
Application number
SG11201903659WA
Inventor
Min Cristina De
Walter Ferlin
Benedetti Fabrizio De
Original Assignee
Novimmune Sa
Min Cristina De
Walter Ferlin
Benedetti Fabrizio De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa, Min Cristina De, Walter Ferlin, Benedetti Fabrizio De filed Critical Novimmune Sa
Publication of SG11201903659WA publication Critical patent/SG11201903659WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 03 May 2018 (03.05.2018) WIP0 I PCT ill~~~~~~~~ 011101010VIIIOH olo olo mo Em (10) International Publication Number WO 2018/078442 A3 (51) International Patent Classification: A61K 39/395 (2006.01) CO7K 16/28 (2006.01) A61K 31/00 (2006.01) A61K 39/00 (2006.01) CO7K 16/24 (2006.01) (21) International Application Number: PCT/IB2017/001427 (22) International Filing Date: Published: — with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (88) Date of publication of the international search report: 23 August 2018 (23.08.2018) 24 October 2017 (24.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/411,783 24 October 2016 (24.10.2016) US (71) Applicant: NOVIMMUNE SA [CH/CH]; 14 Chemin des Aulx, 1228 Plane-les-Ouates (CH). (72) Inventors; and (71) Applicants: DE MIN, Cristina [CH/CH]; 14 Chemin des Aulx, 1228 Plane-les-Ouates (CH). FERLIN, Wal- ter [CH/CH]; 14 Chemin des Aulx, 1228 Plane-les-Ouates (CH). DE BENEDETTI, Fabrizio [CH/CH]; 14 Chemin des Aulx, 1228 Plane-les-Ouates (CH). (74) Agent: WRAIGE, David Leslie Charles et al.; Cooley (UK) LLP, Dashwood, 69 Old Broad Street, London EC2M 1QS (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, *!IC KM, ML, MR, NE, SN, TD, TG). cc N O 00 O (54) Title: METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAM- MA RELATED INDICATIONS C (57) : The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-y levels.
SG11201903659WA 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications SG11201903659WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662411783P 2016-10-24 2016-10-24
PCT/IB2017/001427 WO2018078442A2 (en) 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Publications (1)

Publication Number Publication Date
SG11201903659WA true SG11201903659WA (en) 2019-05-30

Family

ID=60957345

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903659WA SG11201903659WA (en) 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Country Status (12)

Country Link
EP (1) EP3528845A2 (en)
JP (2) JP2019532970A (en)
KR (1) KR20190071785A (en)
CN (1) CN110167593A (en)
AU (1) AU2017352033A1 (en)
BR (1) BR112019008156A2 (en)
CA (1) CA3041434A1 (en)
EA (1) EA201990930A1 (en)
IL (1) IL266174B2 (en)
MX (1) MX2019004766A (en)
SG (1) SG11201903659WA (en)
WO (1) WO2018078442A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118165113A (en) * 2016-04-26 2024-06-11 科济生物医药（上海）有限公司 Method for improving immune response cell function
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
WO2021185832A1 (en) 2020-03-16 2021-09-23 Swedish Orphan Biovitrum Ag New therapeutic treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU764211C (en) * 1998-12-01 2006-03-30 Abbvie Biotherapeutics Inc. Humanized antibodies to gamma-interferon
MX2007008719A (en) 2005-01-27 2007-09-11 Novimmune Sa Human anti-interferon gamma antibodies and methods of use thereof.
CN101896163A (en) * 2007-12-21 2010-11-24 弗·哈夫曼-拉罗切有限公司 Antibody formulation
EP2791168A1 (en) * 2011-11-23 2014-10-22 Amgen Inc. Methods of treatment using an antibody against interferon gamma
KR20170018810A (en) * 2014-06-10 2017-02-20 메이지 세이카 파루마 가부시키가이샤 Stable aqueous adalimumab preparation
MX2017014294A (en) * 2015-05-07 2018-08-09 Novimmune Sa Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers.

Also Published As

Publication number Publication date
IL266174A (en) 2019-06-30
EA201990930A1 (en) 2019-11-29
WO2018078442A3 (en) 2018-08-23
WO2018078442A2 (en) 2018-05-03
JP7562074B2 (en) 2024-10-07
MX2019004766A (en) 2019-09-27
AU2017352033A1 (en) 2019-06-06
IL266174B1 (en) 2024-06-01
JP2019532970A (en) 2019-11-14
CA3041434A1 (en) 2018-05-03
KR20190071785A (en) 2019-06-24
EP3528845A2 (en) 2019-08-28
CN110167593A (en) 2019-08-23
IL266174B2 (en) 2024-10-01
BR112019008156A2 (en) 2019-07-02
JP2022187025A (en) 2022-12-15

Similar Documents

Publication Publication Date Title
SG11201909949XA (en) Targeted immunotolerance
SG11201808990QA (en) Compositions for topical application of compounds
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201811432WA (en) Rna for cancer therapy
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201903604PA (en) Iot security service
SG11201907744QA (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201907023UA (en) Method of reducing neutropenia
SG11201909322VA (en) Treatment of asthma with anti-tslp antibody
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201810872UA (en) Composition and method for reducing neutropenia
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201805001UA (en) Method of treating influenza a
SG11201907774VA (en) Sulfoximine glycosidase inhibitors
SG11201907420VA (en) Inhibition of smarca2 for treatment of cancer
SG11201810786RA (en) [bis(trihydrocarbylsilyl)aminosilyl]-functionalized styrene and a method for its preparation
SG11201807949WA (en) Engineered immunoglobulins with altered fcrn binding